The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth

被引:2
|
作者
Qian, Jing [1 ,8 ]
Ma, Yanxia [1 ,7 ]
Tahaney, William M. [1 ,2 ,6 ]
Moyer, Cassandra L. [1 ]
Lanier, Amanda [1 ]
Hill, Jamal [1 ]
Coleman, Darian [1 ]
Koupaei, Negar [1 ,4 ]
Hilsenbeck, Susan G. [3 ]
Savage, Michelle I. [1 ]
Page, Brent D. G. [5 ]
Mazumdar, Abhijit [1 ]
Brown, Powel H. [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
[3] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Dan L Duncan Canc Ctr, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX USA
[5] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
[6] Monte Rosa Therapeut, Boston, MA USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX USA
[8] Univ Texas MD Anderson Canc Ctr, UTHealth Houston Grad Sch Biomed Sci, Houston, TX USA
关键词
Phosphatase; Triple-negative breast cancer; Oxidative stress; EXPRESSION;
D O I
10.1186/s13058-024-01778-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundThe most aggressive form of breast cancer is triple-negative breast cancer (TNBC), which lacks expression of the estrogen receptor (ER) and progesterone receptor (PR), and does not have overexpression of the human epidermal growth factor receptor 2 (HER2). Treatment options for women with TNBC tumors are limited, unlike those with ER-positive tumors that can be treated with hormone therapy, or those with HER2-positive tumors that can be treated with anti-HER2 therapy. Therefore, we have sought to identify novel targeted therapies for TNBC. In this study, we investigated the potential of a novel phosphatase, NUDT5, as a potential therapeutic target for TNBC.MethodsThe mRNA expression levels of NUDT5 in breast cancers were investigated using TCGA and METABRIC (Curtis) datasets. NUDT5 ablation was achieved through siRNA targeting and NUDT5 inhibition with the small molecule inhibitor TH5427. Xenograft TNBC animal models were employed to assess the effect of NUDT5 inhibition on in vivo tumor growth. Proliferation, death, and DNA replication assays were conducted to investigate the cellular biological effects of NUDT5 loss or inhibition. The accumulation of 8-oxo-guanine (8-oxoG) and the induction of gamma H2AX after NUDT5 loss was determined by immunofluorescence staining. The impact of NUDT5 loss on replication fork was assessed by measuring DNA fiber length.ResultsIn this study, we demonstrated the significant role of an overexpressed phosphatase, NUDT5, in regulating oxidative DNA damage in TNBCs. Our findings indicate that loss of NUDT5 results in suppressed growth of TNBC both in vitro and in vivo. This growth inhibition is not attributed to cell death, but rather to the suppression of proliferation. The loss or inhibition of NUDT5 led to an increase in the oxidative DNA lesion 8-oxoG, and triggered the DNA damage response in the nucleus. The interference with DNA replication ultimately inhibited proliferation.ConclusionsNUDT5 plays a crucial role in preventing oxidative DNA damage in TNBC cells. The loss or inhibition of NUDT5 significantly suppresses the growth of TNBCs. These biological and mechanistic studies provide the groundwork for future research and the potential development of NUDT5 inhibitors as a promising therapeutic approach for TNBC patients.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Novel prognostic markers for patients with triple-negative breast cancer
    Zhou, Ling
    Li, Ke
    Luo, Yanli
    Tian, Ling
    Wang, Min
    Li, Chuanyuan
    Huang, Qian
    HUMAN PATHOLOGY, 2013, 44 (10) : 2180 - 2187
  • [32] Novel immune targets for the treatment of triple-negative breast cancer
    Corti, Chiara
    Nicolo, Eleonora
    Curigliano, Giuseppe
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (10) : 815 - 834
  • [33] Repurposing Drugs as Novel Triple-negative Breast Cancer Therapeutics
    Das, Amiya
    Agarwal, Pallavi
    Jain, Gaurav Kumar
    Aggarwal, Geeta
    Lather, Viney
    Pandita, Deepti
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (03) : 515 - 550
  • [34] Novel therapeutic strategies in the treatment of triple-negative breast cancer
    Oualla, Karima
    El-Zawahry, Heba M.
    Arun, Banu
    Reuben, James M.
    Woodward, Wendy A.
    El-Din, Heba Gamal
    Lim, Bora
    Mellas, Nawfel
    Ueno, Naoto T.
    Fouad, Tamer M.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (07) : 493 - 511
  • [35] Triple-negative breast cancer: new perspectives for novel therapies
    Yashin A. Mahamodhossen
    Wei Liu
    Zhou Rong-Rong
    Medical Oncology, 2013, 30
  • [36] Novel therapy for locally advanced triple-negative breast cancer
    Yamada, Atsuko
    Osada, Shinji
    Tanahashi, Toshiyuki
    Matsui, Satoshi
    Sasaki, Yoshiyuki
    Tanaka, Yoshihiro
    Okumura, Naoki
    Matsuhashi, Nobuhisa
    Takahashi, Takao
    Yamaguchi, Kazuya
    Yoshida, Kazuhiro
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (04) : 1266 - 1272
  • [37] Attempt to suppress triple-negative breast cancer growth by adiponectin
    Chikaishi, Wakana
    Higashi, Toshiya
    Hayashi, Hirokatsu
    Hanamatsu, Yuki
    Kito, Yusuke
    Futamura, Manabu
    Matsuhashi, Nobuhisa
    Saigo, Chiemi
    Takeuchi, Tamotsu
    CANCER SCIENCE, 2024, 115 : 2116 - 2116
  • [38] Novel therapeutic strategies for patients with triple-negative breast cancer
    Zhang, Jun-Fei
    Liu, Jia
    Wang, Yu
    Zhang, Bin
    ONCOTARGETS AND THERAPY, 2016, 9 : 6519 - 6528
  • [39] Triple-negative breast cancer: new perspectives for novel therapies
    Mahamodhossen, Yashin A.
    Liu, Wei
    Rong-Rong, Zhou
    MEDICAL ONCOLOGY, 2013, 30 (03)
  • [40] Novel targeted therapy development in triple-negative breast cancer
    Ueno, Naoto T.
    ANNALS OF ONCOLOGY, 2021, 32 : S258 - S258